cyclizine lactate
Trade name: marezine
Approved
Sep 24, 1954
Cyclizine (cyclizine hydrochloride, Valoid®) is a histamine H1 antagonist of the piperazine class which is characterised by a low incidence of drowsiness. It possesses anticholinergic and antiemetic properties. The exact mechanism by which cyclizin (cyclizine hydrochloride, Valoid®) can prevent or suppress both nausea and vomiting from various causes is unknown. It increases lower oesophageal sphincter tone and reduces the sensitivity of the labyrinthine apparatus. It may inhibit the part of the midbrain known collectively as the emetic centre. — NCATS
Clinical trial activity
4 trials · 4 clinical orgs · 1 marketing orgs
Earliest trial started Mar 1, 2015 (NCT02288923)
Timeline
1950s
- Sep 24, 1954
GlaxoSmithKline — Earliest FDA Approval
- Sep 24, 1954
GlaxoSmithKline — NDA Organization
- Sep 24, 1954
GlaxoSmithKline — NDA Secondary Org
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Approved for
Studied for
Mechanism of action
- Histamine H1 receptorANTAGONIST
HRH1 antagonist
Approval history
- approvedSep 24, 1954
Chemistry & pharmacology
SMILES
CN1CCN(CC1)C(C2=CC=CC=C2)C3=CC=CC=C3- Mol. weight
- 266.3807 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Discontinued
Oral
No
Parenteral
Yes
Topical
No
Sources
- WikipediaCyclizine ↗
- NCATSQRW9FCR9P2 ↗
- ChEMBLCHEMBL648 ↗
- ChEMBLCHEMBL1324714 ↗
- ChEMBLCHEMBL1200497 ↗
Also known as
- 1-benzhydryl-4-methylpiperazin
- 1-benzhydryl-4-methylpiperazin
- (+-)-1-diphenylmethyl-4-methylpiperazine
- (+-)-1-diphenylmethyl-4-methylpiperazine
- (±)-1-diphenylmethyl-4-methylpiperazine
- (±)-1-diphenylmethyl-4-methylpiperazine
- 1-(diphenylmethyl)-4-methylpiperazine
- 1-(diphenylmethyl)-4-methylpiperazine
- ciclizina
- ciclizina
- cyclizine
- cyclizine
- cyclizine
- cyclizine
- cyclizine
- cyclizine
- cyclizine
- cyclizine
- cyclizine
- cyclizine
- cyclizine
- cyclizine hcl
- cyclizine hcl
- cyclizine hcl
- cyclizine lactate
- cyclizine lactate
- cyclizine lactate
- cyclizine lactate
- cyclizinum
- cyclizinum
- marezine
- marezine
- marezine
- marezine
- marzine
- marzine
- nautazine
- (n-benzhydryl)(n'-methyl)diethylenediamine
- (n-benzhydryl)(n'-methyl)diethylenediamine
- n-benzhydryl-n'-methylpiperazine
- n-benzhydryl-n'-methylpiperazine
- n-methyl-n'-benzhydrylpiperazine
- n-methyl-n'-benzhydrylpiperazine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03931135 | N/A | Sep 1, 2019 | Assiut University |
| NCT02009306 | Phase 4 | Jan 23, 2017 | Gloucestershire Hospitals NHS Foundation Trust |
| NCT02905019 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2016 | University of Oxford |
| NCT02288923 | N/A | Mar 1, 2015 | University of Exeter |
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Assiut University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Gloucestershire Hospitals NHS Foundation Trust | Academic/Hospital | 1 | 1 | 1 | 2017 |
| University of Exeter | Academic/Hospital | 1 | 1 | 1 | 2015 |
| University of Oxford | Academic/Hospital | 1 | 1 | 1 | 2016 |
Marketing (2)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| GlaxoSmithKline | For profit | NDA | Sep 24, 1954 |
| GlaxoSmithKline | For profit | NDA2 | Sep 24, 1954 |